Binodenoson

Drug Profile

Binodenoson

Alternative Names: Binodisine; CorVue; MRE 0470; MRE-0740

Latest Information Update: 26 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aderis Pharmaceuticals (CEASED)
  • Developer King Pharmaceuticals Research and Development
  • Class Heart failure therapies; Purine nucleosides; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 22 Oct 2009 King Pharmaceuticals receives complete response letter from the FDA for adjunctive binodenoson in Cardiovascular disorders diagnosis
  • 19 Dec 2008 Preregistration for Cardiovascular disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top